Fight Aging! Newsletter, February 26th 2024
In conclusion, mTORC1 signaling contributes to the ISC fate decision, enabling regional control of intestinal cell differentiation in response to nutrition.
« Back to Top
Reviewing the Development of Senotherapeutics to Treat Aging
https://www.fightaging.org/archives/2024/02/reviewing-the-development-of-senotherapeutics-to-treat-aging/
Senescent cells accumulate with age and contribute meaningfully to chronic inflammation and degenerative aging. Destroying these cells produces rapid and sizable reversal of age-related diseases in mice, demonstrating that the presence of senescence cells ...
Source: Fight Aging! - February 25, 2024 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
An Update on Kimer Med, Improving on the DRACO Antiviral Technology and Moving Towards the Clinic
The state of anti-viral therapies isn't that great, all things considered. Technology has not yet advanced to the point at which a viral infection can be simply shut down, as is the case for near all bacterial infections. The present anti-viral drugs are either vaccines (useful!) or merely shift the odds somewhat by interfering in some part of the viral life cycle, but nowhere near as effectively as desired. Many persistent viral infections are thought to contribute meaningfully to forms of age-related dysfunction, and there is too little that can be done about that at the present time.
This landscape is one of the ...
Source: Fight Aging! - February 23, 2024 Category: Research Authors: Reason Tags: Longevity Industry Source Type: blogs
Circulating Claudin-5 Correlates with Age and Alzheimer's Disease
In this study, we developed a blood-based assay for CLDN-5 and investigated its diagnostic utility using 100 cognitively normal (control) subjects, 100 patients with MCI, and 100 patients with AD. Plasma CLDN-5 levels were increased in patients with AD (3.08 ng/mL) compared with controls (2.77 ng/mL).
The BBB functions as a selective gate for the uptake of essential molecules from blood into the brain and the excretion of harmful molecules from the brain into blood via transporters and receptors on cellular membranes. In addition, the BBB prevents the influx of blood-borne neurotoxins, cells, and pathogens into the ...
Source: Fight Aging! - February 21, 2024 Category: Research Authors: Reason Tags: Daily News Source Type: blogs
Astrocyte Reactivity in the Development of Alzheimer's Disease
Glial fibrillary acidic protein (GFAP) consistently shows up in proteomic analyses of age-related neurodegenerative processes, particularly now that more research groups are engaged in building early warning biomarker profiles for the later development of Alzheimer's disease. Such studies are usually focused on Alzheimer's disease because that is where most neuroscience funding is directed, but the presence of GFAP as a marker is more generally applicable to the aging of the brain and its supporting cell populations.
Astrocyte cells exhibit increased expression of GFAP when they become reactive, it is a well-known m...
Source: Fight Aging! - February 20, 2024 Category: Research Authors: Reason Tags: Medicine, Biotech, Research Source Type: blogs
Circulating Protein Biomarkers Correlate with Future Risk of Dementia
Researchers here demonstrate a predictive biomarker panel for Alzheimer's disease risk based on protein levels assessed in a blood sample. This is a one of a number of similar tests developed in recent years. The question is what one might do given a measurement that suggests high risk of Alzheimer's disease. At present, the only option is to generally improve lifestyle choices, but Alzheimer's is not as correlated with lifestyle factors as is the case for, say, type 2 diabetes. Based on the suggestion that senescent cells are important to neurodegeneration, one might take senolytic drugs intermittently, a few times a year...
Source: Fight Aging! - February 20, 2024 Category: Research Authors: Reason Tags: Daily News Source Type: blogs
To What Degree is Alzheimer's Disease a Modern Phenomenon?
Here find an interesting commentary on what might be gleaned of the prevalence of Alzheimer's disease in antiquity from the body of ancient writings on the topic of aging, memory, and health. The consensus is that Alzheimer's disease is a creation of modernity, some combination of a longer life expectancy for a greater fraction of the population coupled with increased calorie intake and less active lives. Yet unlike type 2 diabetes, risk of Alzheimer's risk doesn't correlate well with the usual suspect lifestyle choices that raise the risk of age-related disease and lower life expectancy.
This line of thinking has l...
Source: Fight Aging! - February 19, 2024 Category: Research Authors: Reason Tags: Medicine, Biotech, Research Source Type: blogs
Fight Aging! Newsletter, February 19th 2024
This study aimed to explore the metabolic mechanisms and potential biomarkers associated with declining HGS among older adults. We recruited 15 age- and environment-matched inpatients (age, 77-90 years) with low or normal HGS. Liquid chromatography-mass spectrometry (LC-MS) and 16S ribosomal DNA (rDNA) gene sequencing were performed to analyze the metabolome of serum and stool samples and the gut microbiome composition of stool samples. Spearman's correlation analysis was used to identify the potential serum and fecal metabolites associated with HGS.
We assessed the levels of serum and fecal metabolites belonging to...
Source: Fight Aging! - February 18, 2024 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Oxidative Stress and Cellular Senescence in Alzheimer's Disease
In this paper, the authors discuss the overlap between oxidative stress and growing numbers of senescent cells in the brain. Both are thought to contribute to neurodegenerative conditions such as Alzheimer's disease. The aging of the brain is complex, a web of interacting processes, causes, and consequences. It has proven to be difficult to determine which processes are more or less important; the only efficient way forward is to come up with interventions that remove just one contributing factor with minimal side-effects. That is now possible for senescent cells, and clinical trials are underway, but manipulation of oxida...
Source: Fight Aging! - February 12, 2024 Category: Research Authors: Reason Tags: Daily News Source Type: blogs
Considering the Near Future of Senotherapeutics
Senescent cells accumulate with age, and this accumulation drives a sizable fraction of the dysfunction of degenerative aging. While never present in very large numbers, these cells energetically secrete signal molecules that provoke inflammation and tissue remodeling. As noted here, a major theme in the development of senotherapeutic drugs to either selectively destroy senescent cells or broadly suppress the disruptive signaling of senescent cells is the need for greater understanding of the diversity of cellular senescence. Different tissues, different cell types, different origins of the senescent state may all be meani...
Source: Fight Aging! - February 12, 2024 Category: Research Authors: Reason Tags: Daily News Source Type: blogs
Fight Aging! Newsletter, February 12th 2024
In conclusion, frailty is a dynamic process, and improved frailty and remaining robust are significantly associated with lower risk of all-cause mortality and cardiovascular death in older people.
« Back to Top
Greater Individual Wealth Correlates with Longer Life Expectancy
https://www.fightaging.org/archives/2024/02/greater-individual-wealth-correlates-with-longer-life-expectancy/
Individual wealth correlates with life expectancy, with an effect size that is in the same ballpark as those related to lifestyle choices involving exercise, diet, and consequences thereof. It remains unclear...
Source: Fight Aging! - February 11, 2024 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Systematic review finds more clinical harm than benefits in Alzheimer ’s “treatments” lecanemab, aducanumab, and donanemab
CONCLUSIONS: Although monoclonal antibodies targeting amyloid provide small benefits on cognitive and functional scales in patients with Alzheimer dementia, these improvements are far below the MCID for each outcome and are accompanied by clinically meaningful harms.
The Study in Context:
Should doctors prescribe lecanemab (Leqembi) to women? The answer, given available evidence, is probably No
First, do no harm? Six reasons to approach anti-amyloid drug Aduhelm cautiously, if at all
Report: 35% of worldwide dementia cases could be prevented by modifying these 9 modifiable risk factors
The post Systematic review fi...
Source: SharpBrains - February 9, 2024 Category: Neuroscience Authors: SharpBrains Tags: Brain/ Mental Health aducanumab Alzheimer's drug Alzheimers-treatment brain bleeds brain swelling cognition dementia donanemab FDA lecanemab Leqembi Medicare Mini-Mental State test minimal clinically important difference mono Source Type: blogs
Bypassing Causes to Focus on Repairing Damaged Synapses in Alzheimer's Disease
Should we expect an approach focused on repair of synapses in neurodegenerative conditions like Alzheimer's disease, while leaving the causative mechanisms of the condition operating intact, to have a large effect on patient outcomes? Given what is known of the underlying mechanisms of protein aggregation, neuroinflammation, and other problems that ultimately kill neurons, not just damage them, it seems possible that synaptic repair might do well in the early stages of cognitive impairment, but later do little to help as the condition progresses. Regardless, it is interesting to consider to degree to which neural function ...
Source: Fight Aging! - February 9, 2024 Category: Research Authors: Reason Tags: Daily News Source Type: blogs
Study Exposes The Hidden Cause Of The Worst Alzheimer ’ s Symptoms (M)
The unforeseen impact of the brain's immune cells on the most perplexing symptoms of Alzheimer's disease. (Source: PsyBlog | Psychology Blog)
Source: PsyBlog | Psychology Blog - February 6, 2024 Category: Psychiatry & Psychology Authors: Jeremy Dean Tags: Dementia subscribers-only Source Type: blogs
A New Day for Parkinson ’s Disease Research Is Near
By STEVEN ZERCOLA
The U.S. Department of Health and Human Service (“HHS”) is responsible for a wide range of activities relating to medical and public health. It has 60,000 employees and a $1.7 trillion annual budget with approximately $140 billion for discretionary spending. For the past 13 years, HHS has been spearheading a National Plan for addressing Alzheimer’s disease – with some notable successes.
Given its resources, expertise and charter, HHS should launch a National Plan to cure Parkinson’s disease patterned after its approach on Alzheimer’s disease.
Legislation, or Not
The U.S. House of R...
Source: The Health Care Blog - February 6, 2024 Category: Consumer Health News Authors: matthew holt Tags: Health Policy Drug discovery FDA Parkinson's Disease steve zecola Source Type: blogs
